Advertisement

Geriatric Oncology

Co-occurrence of Cancer and Cognitive Impairment in Older Adults

The prevalence of both cancer and cognitive impairment increases with age.1-3 Based upon Surveillance, Epidemiology, and End Results (SEER)-Medicare studies, it is estimated that 3% to 7% of patients with cancer aged ≥ 65 also suffer from dementia, although the true prevalence of dementia in this population is likely higher, given the probable lack of capture in claims data.4,5 This figure also does not include individuals with mild cognitive impairment, an earlier stage of memory loss. Mild cognitive impairment affects an estimated 22.2% of Americans over the age of 70.2

 

Breast Cancer

Confirmation or Transformation? The Case of Palbociclib in Hormone Receptor–Positive Metastatic Breast Cancer

Women with hormone receptor–positive metastatic breast cancer are witnessing an unprecedented time of success in the battle against their disease. Just in the past 12 months, a number of prospective, randomized, phase III studies were reported, with positive results indicating the value of fulvestrant (Faslodex) as a single agent in endocrine-naive cases but most important establishing a completely new standard of care in the management of advanced breast cancer. A new class of drugs, the cyclin-dependent kinase (CDK) 4/6 inhibitors, demonstrated in every large prospective study a significant superiority in comparison to single-agent endocrine therapy, and this benefit was associated with relatively minimal and tolerable toxicity. The most recent and significant study, PALOMA-2 was published by Finn et al in the November issue of The New England Journal of Medicine1 and is reviewed in this issue of The ASCO Post.

Palliative Care

Weighing the Benefits and Risks of Medical Marijuana

Despite the fact that 28 states and the District of Columbia have enacted laws to permit the use of cannabis and cannabinoid-based drugs to treat medical conditions, including cancer and symptoms from its treatment, federal law prohibits physicians from prescribing marijuana to their patients, creating a delicate legal—and ethical—dilemma for physicians.


Advertisement

More Top Stories

Breast Cancer

Lisa A. Carey, MD, on SABCS Meeting Highlights: Expert Perspective

Breast Cancer

Abemaciclib Plus Anastrozole: Promising Signals Reported in Phase II Study of Early Breast Cancer

As neoadjuvant therapy, abemaciclib alone or in combination with anastrozole achieved strong signals of anticancer activity in postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer in the neoMONARCH phase II study.1 Abemaciclib alone or in combination with anastrozole...

Advertisement

Fear of Diagnostic Low-Dose Radiation Exposure May Be Overstated, Experts Assert

In an article published by Siegel et al in The Journal of Nuclear Medicine, researchers assert that exposure to medical radiation does not increase a person’s risk of getting cancer. The long-held belief that even low doses of radiation, such as those received in diagnostic imaging, increase...

Breast Cancer
Symptom Management

Patricia A. Ganz, MD: Aromatase Inhibitors Data Review

American Cancer Society Welcomes Three New Members and Newly Elected Officers to Board of Directors

The American Cancer Society announced the election of three new members—Amit Kumar, PhD, Joseph M. Naylor, and William D. Novelli—to the 2017 American Cancer Society Board of Directors. In addition, the new key officer leadership positions were announced, which include Arnold M....

Breast Cancer
Genomics/Genetics

BRCA Status Does Not Seem to Affect Survival Outcomes in Young Women With Early Breast Cancer

Young women who carry the BRCA1 and/or BRCA2 mutation and develop breast cancer seem to have similar survival compared with young women who have BRCA-negative breast cancer. However, women with BRCA-positive triple-negative breast cancer have an 11% survival advantage compared with those with...

FDA Approves Morphine Sulfate Extended-Release Tablets Formulated With Abuse-Deterrent Properties

On January 9, the U.S. Food and Drug Administration (FDA) approved morphine sulfate extended-release tablets formulated with abuse-deterrent properties (Arymo ER) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative...

Lymphoma

Laurie H. Sehn, MD, MPH, on Follicular Lymphoma: Choosing the Best Target

Breast Cancer
Genomics/Genetics

BRCA Status Does Not Seem to Affect Survival Outcomes in Young Women With Early Breast Cancer

Young women who carry the BRCA1 and/or BRCA2 mutation and develop breast cancer seem to have similar survival compared with young women who have BRCA-negative breast cancer. However, women with BRCA-positive triple-negative breast cancer have an 11% survival advantage compared with those with...

Advertisement

FDA Accepts sBLA and Grants Priority Review for Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma

On January 9, the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for atezolizumab (Tecentriq) in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin...


click me